13F Holdings
中文EN

IVA Inventiva S.A. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1756594 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY43.5%
TTM net income YoY-103.5%
TTM EPS YoY-85.5%
Revenue 3-yr CAGR260.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-587.7%
Net margin-631.8%
FCF margin—
EBITDA margin—

Returns

ROE-1,642.8%
ROA-119.0%
ROIC (approx.)—
Asset turnover0.19x

Leverage & solvency

Liabilities / assets146.0%
Debt / equity—
Current ratio0.96x
Interest coverage-19.84x

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-31.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31FY2020*2020-12-31
Income statement
Revenue9.20M17.48M12.18M4.19M372,000
R&D expense90.88M110.01M60.47M48.45M23.72M
SG&A expense15.84M13.84M12.91M11.15M8.50M
Operating income-97.56M-102.71M-57.11M-52.11M-29.72M
Interest expense12.18M5.18M584,000138,00066,000
Income tax313,000607,000-20,000364,0000
Net income-184.21M-110.43M-54.27M-49.63M-33.62M
EPS (basic)-3.08-2.43-1.31-1.27-0.99
EPS (diluted)-3.08-2.43-1.31-1.27-0.99
Weighted avg. shares (diluted)59.78M45.35M41.45M39.17M33.87M
Balance sheet
Cash & equivalents96.56M26.92M86.74M86.55M105.69M
Short-term investments—10,0001.00M8.80M—
Receivables531,0003.81M04.00M48,000
Inventory0417,000373,000392,000320,000
Current assets111.51M48.19M106.38M115.58M133.00M
PP&E, netmay include right-of-use assets (IFRS)5.00M9.12M7.39M3.20M3.28M
Intangibles48,000541,000568,000770,000935,000
Total assets118.97M69.56M116.00M121.98M138.92M
Current liabilities120.73M50.16M30.70M22.85M13.91M
Short-term debt——5.85M1.28M18,000
Long-term debt——28.66M8.84M10.04M
Total debt——34.51M10.12M10.05M
Total liabilities225.61M101.59M70.53M33.12M27.71M
Shareholders' equity-106.65M-32.03M45.48M88.87M111.21M
Net debt——-52.22M-76.43M-95.63M
Shares outstanding95.66M52.12M42.13M40.87M38.63M
Cash flow statement
Operating cash flow-85.93M-81.61M-44.93M-47.63M-30.59M
Investing cash flow8.74M-7.73M8.87M-1.79M-8.56M
Financing cash flow145.59M29.08M37.27M25.45M111.67M
Stock-based compensation3.58M3.97M2.22M2.09M938,000

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.